

Publications for Gopala Rangan

2018

Wishart, T., Aw, L., Byth, K., Rangan, G., Sud, K. (2018). A retrospective sequential comparison of topical application of medicated honey and povidone iodine for preventing peritoneal dialysis catheter-related infections. *Peritoneal Dialysis International*, 38(4), 302-305. [More Information]

Oey, O., Rao, P., Luciuk, M., Mannix, C., Rogers, N., Sagar, P., Wong, A., Rangan, G. (2018). Effect of dimethyl fumarate on renal disease progression in a genetic ortholog of nephronophthisis. *Experimental Biology and Medicine*, 243(5), 428-436. [More Information]

Tasneem, M., Mannix, C., Wong, A., Zhang, J., Rangan, G. (2018). Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease? *World Journal of Nephrology*, 7(2), 51-57. [More Information]

Wong, A., Mannix, C., Grantham, J., Allman-Farinelli, M., Badve, S., Boudville, N., Byth, K., Chan, J., Coulshed, S., Edwards, M., Foster, S., Harris, D., Howard, K., Howell, M., Lee, V., Rangan, A., Sud, K., Rangan, G., et al (2018). Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD). *BMJ Open*, 8(1), 1-13. [More Information]

Mannix, C., Rangan, G., Wong, A., Zhang, J., Allman-Farinelli, M., Rangan, A. (2018). Relative Validity of a Beverage Frequency Questionnaire Used to Assess Fluid Intake in the Autosomal Dominant Polycystic Kidney Disease Population. *Nutrients*, 10(8), 1-11. [More Information]

2017

Fernando, M., Dent, H., McDonald, S., Rangan, G. (2017). Incidence and survival of end-stage kidney disease due to polycystic kidney disease in Australia and New Zealand (1963-2014). *Population Health Metrics*, 15(1), 1-12. [More Information]

Cho, Y., Sautenet, B., Rangan, G., Craig, J., Ong, A., Chapman, A., Ahn, C., Chen, D., Coolican, H., Kao, J., Gutman, T., Howell, M., Ju, A., Manera, K., Teixeira-Pinto, A., Hamiwka, L., Tong, A., et al (2017). Standardised Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD): Study protocol for establishing a core outcome set in polycystic kidney disease. *Trials*, 18(1), 1-11. [More Information]

2016

Chua, T., Prasad, N., Rangan, G., Allman-Farinelli, M., Rangan, A. (2016). A systematic review to determine the most effective interventions to increase water intake. *Nephrology*,

21(10), 860-869. [More Information]

Rangan, G. (2016). C5b-9 does not mediate tubulointerstitial injury in experimental acute glomerular disease characterized by selective proteinuria. *World Journal of Nephrology*, 5(3), 288-299. [More Information]

Ta, M., Schwensen, K., Liuwantara, D., Huso, D., Watnick, T., Rangan, G. (2016). Constitutive renal Rel/nuclear factor-(kappa)B expression in Lewis polycystic kidney disease rats. *World Journal of Nephrology*, 5(4), 339-357. [More Information]

Ta, M., Schwensen, K., Foster, S., Korgaonkar, M., Ozimek-Kulik, J., Phillips, J., Peduto, A., Rangan, G. (2016). Effects of TORC1 inhibition during the early and established phases of polycystic kidney disease. *PLoS One*, 11(10), 1-30. [More Information]

Succar, L., Boadle, R., Harris, D., Rangan, G. (2016). Formation of tight junctions between neighboring podocytes is an early ultrastructural feature in experimental crescentic glomerulonephritis. *International Journal of Nephrology and Renovascular Disease*, 9, 297-312. [More Information]

Tong, A., Tunnicliffe, D., Lopez-Vargas, P., Mallett, A., Patel, C., Savige, J., Campbell, K., Patel, M., Tchan, M., Alexander, S., Lee, V., Craig, J., Rangan, G., et al (2016). Identifying and integrating consumer perspectives in clinical practice guidelines on autosomal-dominant polycystic kidney disease. *Nephrology*, 21(2), 122-132. [More Information]

Lantinga, M., Darding, A., De Siqueira, R., Alam, A., Bleeker-Rovers, C., Bobot, M., Cornec-Le Gall, E., Gevers, T., Hassoun, Z., Rangan, G., et al (2016). International Multi-Specialty Delphi Survey: Identification of Diagnostic Criteria for Hepatic and Renal Cyst Infection. *Nephron Journals*, 134(4), 205-214. [More Information]

Rangan, G., Alexander, S., Campbell, K., Dexter, M., Lee, V., Lopez-Vargas, P., Mai, J., Mallett, A., Patel, C., Patel, M., Tchan, M., Tong, A., Tunnicliffe, D., et al (2016). KHA-CARI guideline recommendations for the diagnosis and management of autosomal dominant polycystic kidney disease. *Nephrology*, 21(8), 705-716. [More Information]

Rangan, G., Tchan, M., Tong, A., Wong, A., Nankivell (Nankievell), B. (2016). Recent advances in autosomal-dominant polycystic kidney disease. *Internal Medicine Journal*, 46(8), 883-892. [More Information]

2015

Tong, A., Rangan, G., Ruospo, M., Saglimbene, V., Strippoli, G., Palmer, S., Tunnicliffe, D., Craig, J. (2015). A painful inheritance-patient perspectives on living with polycystic kidney disease: thematic synthesis of qualitative research. *Nephrology, Dialysis, Transplantation*, 30(5), 790-800. [More Information]

Alexander, S., Rangan, G., Tchan, M., McCarthy, W., Mallett, A., Patel, C., Maier, A., McGaughan, J., Gabbett, M., Takasato, M., et al (2015). A protocol for the identification and validation of novel genetic causes of kidney disease. *BMC Nephrology*, 16(1), 1-10. [More Information]

Rangan, G., Lopez-Vargas, P., Nankivell (Nankievell), B., Tchan, M., Tong, A., Tunnicliffe, D., Savage, J. (2015). Autosomal Dominant Polycystic Kidney Disease: A Path Forward. *Seminars in Nephrology*, 35(6), 524-537. [More Information]

Ta, M., Liuwantara, D., Rangan, G. (2015). Effects of pyrrolidine dithiocarbamate on proliferation and nuclear factor- κ B activity in autosomal dominant polycystic kidney disease cells. *BMC Nephrology*, 16(1), 1-13. [More Information]

Savage, J., Tunnicliffe, D., Rangan, G. (2015). KHA-CARI Autosomal Dominant Kidney Disease Guideline: Management of Chronic Pain. *Seminars in Nephrology*, 35(6), 607-611.e3. [More Information]

Campbell, K., Rangan, G., Lopez-Vargas, P., Tong, A. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Diet and Lifestyle Management. *Seminars in Nephrology*, 35(6), 572-581.e17. [More Information]

Tchan, M., Savage, J., Patel, C., Mallett, A., Tong, A., Tunnicliffe, D., Rangan, G. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Genetic Testing for Diagnosis. *Seminars in Nephrology*, 35(6), 545-549.e2. [More Information]

Patel, C., Tchan, M., Savage, J., Mallett, A., Tong, A., Tunnicliffe, D., Rangan, G. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Genetics and Genetic Counseling. *Seminars in Nephrology*, 35(6), 550-556.e1. [More Information]

Lee, V., Tunnicliffe, D., Rangan, G. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of End-Stage Kidney Disease. *Seminars in Nephrology*, 35(6), 595-602.e12. [More Information]

Lee, V., Dexter, M., Mai, J., Vladica, P., Lopez-Vargas, P., Rangan, G. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of Intracranial Aneurysms. *Seminars in Nephrology*, 35(6), 612-617.e20. [More Information]

Savage, J., Mallett, A., Tunnicliffe, D., Rangan, G. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of Polycystic Liver Disease. *Seminars in Nephrology*, 35(6), 618-622.E5. [More Information]

Mallett, A., Patel, M., Tunnicliffe, D., Rangan, G. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of Renal Stone Disease. *Seminars in Nephrology*, 35(6), 603-606.e3. [More Information]

Mai, J., Lee, V., Lopez-Vargas, P., Vladica, P., Rangan, G. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Monitoring Disease Progression. *Seminars in Nephrology*, 35(6), 565-571.e18. [More Information]

Mallett, A., Lee, V., Mai, J., Lopez-Vargas, P., Rangan, G. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Pharmacological Management. *Seminars in Nephrology*, 35(6), 582-589.e17. [More Information]

Tong, A., Mallett, A., Lopez-Vargas, P., Rangan, G. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Psychosocial Care. *Seminars in Nephrology*, 35(6), 590-594.e5. [More Information]

Rangan, G., Lee, V., Alexander, S., Patel, C., Tunnicliffe, D., Vladica, P. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Screening for Polycystic Kidney Disease. *Seminars in Nephrology*, 35(6), 557-564.e6. [More Information]

Crawford, S., Chen, S., Halliday, C., Rangan, G., Gottlieb, T., Reid, A. (2015). Microsphaeropsis arundinis skin and soft tissue infection in renal transplant recipients: three case reports and a review of the literature. *Transplant Infectious Disease*, 17(6), 915-920. [More Information]

2014

Bose, B., Badve, S., Hiremath, S., Boudville, N., Brown, F., Cass, A., de Zoysa, J., Fassett, R., Faull, R., Harris, D., Perkovic, V., Rangan, G., et al (2014). Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. *Nephrology Dialysis Transplantation*, 29(2), 406-413. [More Information]

Succar, L., Lai-Kwon, J., Nikolic-Paterson, D., Rangan, G. (2014). Induction monotherapy with sirolimus has selected beneficial effects on glomerular and tubulointerstitial injury in nephrotoxic serum nephritis. *International Journal of Nephrology and Renovascular Disease*, 7, 303-313. [More Information]

Chaudhry, R., Rangan, G. (2014). Levels of haloacetic acids in tap water in an urban Australian city and its relevance to autosomal dominant polycystic kidney disease. *Kidney International*, 85(6), 1471-1471. [More Information]

Rangan, G., Nankivell (Nankievell), B. (2014). Management of

autosomal dominant polycystic kidney disease. *Medicine Today*, 15(6), 16-27.

McDonald, S., Rangan, G. (2014). Polycystic kidney disease: Progression of polycystic kidney disease-a lack of progress? *Nature Reviews Nephrology*, 10(9), 489-491. [More Information]

Ta, M., Rao, P., Korgaonkar, M., Foster, S., Peduto, A., Harris, D., Rangan, G. (2014). Pyrrolidine dithiocarbamate reduces the progression of total kidney volume and cyst enlargement in experimental polycystic kidney disease. *Physiological Reports*, 2(12), 1-15. [More Information]

Myint, T., Rangan, G., Webster, A. (2014). Treatments to slow progression of autosomal dominant polycystic kidney disease: systematic review and meta-analysis of randomized trials. *Nephrology*, 19(4), 217-226. [More Information]

2013

Chapman, J., Rangan, G. (2013). Are Nonesterified Fatty Acids Protective in Chronic Allograft Nephropathy? *Transplantation*, 95(11), 1313-1314. [More Information]

Rangan, G., Schwensen, K., Foster, S., Korgaonkar, M., Peduto, A., Harris, D. (2013). Chronic effects of dietary Vitamin D deficiency without increased calcium supplementation on the progression of experimental polycystic kidney disease. *American Journal of Physiology: Renal Physiology*, 305(4), F574-F582. [More Information]

Ta, M., Rao, P., Korgaonkar, M., Foster, S., Peduto, A., Harris, D., Rangan, G. (2013). Pyrrolidine Dithiocarbamate Attenuates Kidney Enlargement in Experimental Polycystic Kidney Disease. *Nephrology*, 18(Supp. 1), 37-37.

Rangan, G., Harris, D. (2013). Rationale and Design of an Observational Study to Determine the Effects of Cholecalciferol on Hypertension, Proteinuria and Urinary MCP-1 in ADPKD. *Current Hypertension Reviews*, 9(2), 115-120. [More Information]

Ta, M., Harris, D., Rangan, G. (2013). Role of interstitial inflammation in the pathogenesis of polycystic kidney disease. *Nephrology*, 18(5), 317-330. [More Information]

2012

Sud, K., Rangan, G. (2012). Peritonitis and Exit-Site Infections. In David Harris, Grahame Elder, Lukas Kairaitis, Gopala Rangan (Eds.), *Pocket Guide to Clinical Dialysis*, (pp. 245-255). Sydney, Australia: McGraw Hill.

Harris, D., Elder, G., Kairaitis, L., Rangan, G. (2012). *Pocket Guide to Clinical Dialysis*. Sydney, Australia: McGraw Hill.

2011

Badve, S., Brown, F., Hawley, C., Johnson, D., Kanellis, J., Rangan, G., Perkovic, V. (2011). Challenges of conducting a trial of uric-acid-lowering therapy in CKD. *Nature Reviews Nephrology*, 7(5), 295-300. [More

Information]

Schwensen, K., Burgess, J., Graf, N., Alexander, S., Harris, D., Phillips, J., Rangan, G. (2011). Early Cyst Growth Is Associated with the Increased Nuclear Expression of Cyclin D1/Rb Protein in an Autosomal-Recessive Polycystic Kidney Disease Rat Model. *Nephron Experimental Nephrology*, 117(4), e93-e103. [More Information]

Succar, L., Harris, D., Rangan, G. (2011). Role of the Mammalian Target of Rapamycin (mTOR) Signalling Pathway in Podocytes in Glomerular Disease. In Sharma S. Prabhakar (Eds.), *An Update on Glomerulopathies - Etiology and Pathogenesis*, (pp. 183-202). Rijeka, Croatia: InTech Publishers. [More Information]

2010

Foster, S., Korgaonkar, M., Rangan, G., Schwensen, K., Peduto, A. (2010). Changes in kidney volume in experimental Polycystic Kidney Disease (PKD) quantified by a clinical 3T MR Scanner. *ISMRM/SMRT Annual Meeting*.

Rangan, G., Burgess, J., Schwensen, K., Harris, D. (2010). Polycystic kidney disease - Part 1. *Medical Observer*, 19 March, 27-29.

Rangan, G., Burgess, J., Schwensen, K., Harris, D. (2010). Polycystic kidney disease - Part 2. *Medical Observer*, 26 March, 29-31.

Schwensen, K., Foster, S., Korgaonkar, M., Peduto, A., Harris, D., Rangan, G. (2010). Sequential assessment of total kidney volume (TKV) in experimental autosomal recessive Polycystic Kidney Disease (ARPKD) using a clinical 3T scanner. *46th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology*.

Schwensen, K., Foster, S., Korgaonkar, M., Peduto, A., Harris, D., Rangan, G. (2010). Sirolimus (S) reduces kidney enlargement but does not improve cystic microarchitecture in established Polycystic Kidney Disease (PKD). *46th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology*.

2009

Zheng, G., Lyons, J., Tan, T., Wang, Y., Hsu, T., Min, D., Succar, L., Rangan, G., Hu, M., Henderson, B., Alexander, S., Harris, D. (2009). Disruption of E-Cadherin by Matrix Metalloproteinase Directly Mediates Epithelial-Mesenchymal Transition Downstream of Transforming Growth Factor- β 1 in Renal Tubular Epithelial Cells. *American Journal of Pathology*, 175(2), 580-591. [More Information]

Rangan, G., Wang, Y., Harris, D. (2009). NF-kappaB signalling in chronic kidney disease. *Frontiers in Bioscience*, 14, 3496-3522. [More Information]

Rangan, G., Nguyen, T., Mainra, R., Succar, L., Schwensen, K., Burgess, J., Ho, K. (2009). Therapeutic role of sirolimus in non-transplant kidney disease. *Pharmacology and Therapeutics*, 123(2), 187-206. [More Information]

2008

Rangan, G. (2008). Haematuria. In David Harris (Eds.), *Clinical Cases in Kidney Disease*, (pp. 63-75). Australia:

McGraw Hill.

Rangan, G., Succar, L. (2008). Rapidly Progressive Glomerulonephritis. In David Harris (Eds.), *Clinical Cases in Kidney Disease*, (pp. 192-204). Australia: McGraw Hill.

Rangan, G. (2008). Renal Mass. In David Harris (Eds.), *Clinical Cases in Kidney Disease*, (pp. 49-62). Australia: McGraw Hill.

2007

Rangan, G., Tesch, G. (2007). Quantification of renal pathology by image analysis (Methods in Renal Research). *Nephrology*, 12(6), 553-558. [More Information]

Rangan, G., Coombes, J. (2007). Renoprotective effects of sirolimus in non-immune initiated focal segmental glomerulosclerosis. *Nephrology, Dialysis, Transplantation*, 22(8), 2175-2182. [More Information]

Phillips, J., Hopwood, D., Loxley, R., Ghatora, K., Coombes, J., Tan, Y., Harrison, J., McKittrick, D., Holobotsky, V., Arnolda, L., Rangan, G. (2007). Temporal relationship between renal cyst development, hypertension and cardiac hypertrophy in a new rat model of autosomal recessive polycystic kidney disease. *Kidney and Blood Pressure Research*, 30(3), 129-144. [More Information]

2006

Lee, V., Wang, Y., Qin, X., Wang, Y., Zheng, G., Mahajan, D., Coombes, J., Rangan, G., Alexander, S., Harris, D. (2006). Adriamycin nephropathy in severe combined immunodeficient (SCID) mice. *Nephrology, Dialysis, Transplantation*, 21(11), 3293-3298. [More Information]

Rangan, G., Kan, G., Steer, J., Dogra, G., Croft, K., Rhodes, H., Woodroffe, A., Joyce, D. (2006). Altered expression of nuclear factor-kappa B in peripheral blood mononuclear cells in chronic haemodialysis patients. *Nephrology, Dialysis, Transplantation*, 21(4), 1137-1139.

Zheng, G., Wang, Y., XIANG, S., Tay, Y., Wu, H., Watson, D., Coombes, J., Rangan, G., Alexander, S., Harris, D. (2006). DNA vaccination with CCL2 DNA modified by the addition of an adjuvant epitope protects against "nonimmune" toxic renal injury. *Journal of the American Society of Nephrology*, 17(2), 465-474. [More Information]

Zhu, G., Wang, Y., Wang, J., Tay, Y., Yung, T., Rangan, G., Harris, D. (2006). Significance of CD25 positive cells and macrophages in nonrescued IgA nephropathy. *Renal Failure*, 28(3), 229-235. [More Information]

Rangan, G. (2006). Sirolimus-associated proteinuria and renal dysfunction. *Drug Safety*, 29(12), 1153-1161. [More Information]

2005

Geevasinga, N., Kairaitis, L., Rangan, G., Coleman, P. (2005). Acute interstitial nephritis secondary to esomeprazole. *Medical Journal of Australia*, 182(5).

eve&db=pubmed&dopt=Abstract&list_uids=15748135">[More Information]

Rangan, G., Kan, G., Steer, J., Dogra, G., Croft, K., Rhodes, H., Woodroffe, A., Joyce, D. (2005). Altered expression of nuclear factor- κ B in peripheral blood mononuclear cells in chronic haemodialysis patients. *Nephrology, Dialysis, Transplantation*, 21, 1137-9. [More Information]

Harris, D., Elder, G., Kairaitis, L., Rangan, G. (2005). *Basic Clinical Dialysis*. Sydney: McGraw-Hill, Medical Pub. Division.

Rangan, G., Pippin, J., Coombes, J., Couser, W. (2005). C5b-9 does not mediate chronic tubulointerstitial disease in the absence of proteinuria. *Kidney International*, 67(2), 492-503. [More Information]

Tay, Y., Wang, Y., Kairaitis, L., Rangan, G., Zhang, C., Harris, D. (2005). Can murine diabetic nephropathy be separated from superimposed acute renal failure? *Kidney International*, 68(1), 391-398. [More Information]

Rangan, G., Wang, Y., Tay, Y., Harris, D. (2005). Differential effects of albumin on cytokine gene expression in proximal tubular epithelial cells. *Nephrology, Dialysis, Transplantation*, 20(5), 1013-1014. [More Information]

Rangan, G., Tay, Y., Harris, D. (2005). Differential effects of albumin on cytokine gene expression in proximal tubular epithelial cells. *Nephrology, Dialysis, Transplantation*, 20(5), 1013-4. [More Information]

Rangan, G., Wang, Y., Harris, D., Tay, Y., Coombes, J. (2005). Effect of nephrotoxins on tubulointerstitial injury and NF-kappaB activation in Adriamycin nephropathy. *Renal Failure*, 27(5), 609-14. [More Information]

Wang, Y., Mahajan, D., Tay, Y., Bao, B., Spicer, T., Kairaitis, L., Rangan, G., Harris, D. (2005). Partial depletion of macrophages by ED7 reduces renal injury in Adriamycin nephropathy. *Nephrology*, 10(5), 470-7. [More Information]

Liddle, C., Rangan, G., Coombes, J., Mreich, E. (2005). Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy. *Kidney International*. [More Information]

Harris, D., Rangan, G. (2005). Retardation of kidney failure -- applying principles to practice. *Annals of the Academy of Medicine, Singapore (AAMS)*, 34(1), 16-23. [More Information]

2004

Rangan, G., Pippin, J., Couser, W. (2004). C5B-9 Regulates Peritubular Myofibroblast Accumulation In Experimental Focal Segmental Glomerulosclerosis. *Kidney International*, 66(5), 1838-1848. [More Information]

2003

Rangan, G., Harris, D. (2003). A blast from the mast? *Kidney International*, 64(3), 1134-1135.

2002

Wang, Y., Harris, D., Rangan, G. (2002). Dietary Quercetin Augments activator Protein-1 and Does Not Reduce Nuclear Factor-KB in the Renal Cortex of Rats with Established Chronic Glomerular Disease. *Nephron Journals*, 90(3), 313-319. [More Information]